Skip to Content
Søk Menu
20.-24. SEPTEMBER 2023

ESMO 2023 | European Society for Medical Oncology

Kom med til Norsk Aften i Madrid
Nadia Harbeck

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Nadia Harbeck
KreftBrystkreftESMO22 Play the Video

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Dermatologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Fastleger / Jon Amund Kyte

The clinical value of circulating tumor DNA in renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

MEDtalks fra ESMO 2022

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Onkologi / Siow Ming Lee

Prostatakreft – høydepunkter fra ESMO 2022

/ Onkologi / Daniel Heinrich

COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab

/ Onkologi / Toni K. Choueiri

Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy

/ Onkologi / Chris Parker

Firstline nivolumab plus ipilimumab shows durable OS after 4 years in patients with pleural mesothelioma

/ Onkologi / Gerard Zalcman

The MCED blood test – A possible new era of early cancer detection

/ Onkologi / Deborah Schrag

Norsk studie øger tilgang til ny behandling basert på molekylære forandringer i kreftsvulsten

/ Onkologi / Sigmund Brabrand / Katarina Puco

The link between air pollution and NSCLC – in people who have never smoked

/ Onkologi / Charles Swanton

Cell therapy improves progression-free survival with 50% in advanced melanoma

/ Onkologi / John Haanen

ESMO | Norsk Aften i Madrid

Vi har gleden av å invitere til Norsk Aften ESMO 2023 i Madrid. Hai Interaktiv og BestPractice Nordic har i år inngått et samarbeid om å arrangere en felles Norsk Aften under ESMO i Madrid

Abstracts fra ESMO 2022

MCED blood test – a gamechanger for early cancer detection

/ BestPractice Nordic
KreftESMO22

Air pollution and lung cancer in never-smoking people 

/ BestPractice Nordic
LungekreftESMO22

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ BestPractice Nordic
MelanomESMO22

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ BestPractice Nordic
BrystkreftESMO22

A major threat to human health

/ BestPractice Nordic
KreftESMO22

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
Gynekologisk kreftESMO22
Load more

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

  • / BestPractice Nordic

Abstracts fra ESMO 2022

ESMO 2022 –» Understanding the disease to provide better care for cancer patients»  

  • / BestPractice Nordic

ESMO 2021 • Highlights

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynekologisk kreft Play the Video
Ma Pilar Barretina-Ginesta

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Ma Pilar Barretina-Ginesta
ESMO21Gynekologisk kreft Play the Video
Roy S. Herbst

Clinical perspective of the COAST-study for unresectable Stage III NSCLC

/ Roy S. Herbst
LungekreftESMO21NSCLC Play the Video
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21NSCLC Play the Video
Load more

ESMO 2021 • Highlights

Camillo Porta

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Camillo Porta
HudkreftESMO21 Play the Video

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Onkologi / Jared Weiss

Perspective of first line immune therapy of non-small-cell lung cancer

/ Onkologi / Ahmet Sezer

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Onkologi / Nir Peled

Potential as new standard treatment of HER2+ metastatic breast cancer

/ Onkologi / Javier Cortés

Nivolumab + chemo – a candidate for a new standard 1L treatment of advanced gastric/esophageal adenocarcinoma

/ Onkologi / Yelena Janjigian

Innhold fra ESMO 2020

Høydosert strålebehandling ved småcellet lungekreft i begrenset stadium

/ Bjørn Henning Grønberg
LungekreftESMO20

ESMO20: Update om lungecancer

/ Bjørn H. Grønberg
LungekreftESMO20 Play the Video

ESMO20: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

/ Julie Brahmer
LungekreftESMO20 Play the Video

PIONeeR-studiet bringer os tættere på forståelsen af resistens mod PD-1/L1 inhibitorer

LungekreftESMO20

Lovende effekt på hjernemetastaser placerer osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

LungekreftESMO20

The AKT inhibitor ipatasertib in combination with abiraterone shows promising results in castration-resistant prostate cancer

BrystkreftESMO20

CDK 4/6-hæmmeren abemacitib i tidlig brystkræft har potentialet til at ændre praksis

BrystkreftESMO20

KEYNOTE 590 – Immunterapi kan blive ny førstelinjebehandling ved avanceret esophaguscancer

KreftESMO20
Mere

Back to top